FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1543-1549 May 27, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The discovery that progesterone blocked ovulation and the development of the combined oral contraceptive pill in the 1950s were landmarks in the control of human fertility^1,2. By providing women with a reliable method of regulating their fertility, the combined oral contraceptive has played an essential part in allowing them to participate fully in society. In spite of initial alarm that it would lead to sexual promiscuity and moral degeneration, the use of hormonal steroids rapidly became widespread and is the most popular method of contraception in most Western countries³.

Methods of Hormonal Contraception

Hormonal contraceptive steroids are available mainly as oral preparations, . . . [Full Text of this Article]

Developments in Combined Oral Contraception

Risks of Combined Oral Contraceptive Agents

Endometrial and Ovarian Cancer

Liver Cancer

Cancer of the Cervix

Breast Cancer

Cardiovascular Disease and Lipid Metabolism

Glucose Tolerance

Hypertension

Contraception with Progestogen Only

New Delivery Systems

Postcoital Contraception

Hormone-Impregnated Intrauterine Devices

Male Contraception

New Developments

Conclusions

Source Information

From the Department of Obstetrics and Gynaecology, Centre for Reproductive Biology, University of Edinburgh, 37 Chalmers St., Edinburgh EH3 9EW, Scotland, where reprint requests should be addressed to Dr. Baird.

References

Related Letters:

Hormonal Contraception
Eluf-Neto J., Booth M., Baird D. T., Glasier A.
Extract | Full Text  
N Engl J Med 1993; 329:1501-1502, Nov 11, 1993. Correspondence

This article has been cited by other articles:

• Shufelt, C. L., Bairey Merz, C. N. (2009). Contraceptive hormone use and cardiovascular disease.. J Am Coll Cardiol 53: 221-231 [Abstract] [Full Text]  
• Lin, J., Zhang, S. M., Cook, N. R., Manson, J. E., Buring, J. E., Lee, I-M. (2007). Oral Contraceptives, Reproductive Factors, and Risk of Colorectal Cancer among Women in a Prospective Cohort Study. Am J Epidemiol 165: 794-801 [Abstract] [Full Text]  
• Feinberg, E. C., Bromer, J. G., Catherino, W. H. (2005). The Evolution of in Vitro Fertilization: Integration of Pharmacology, Technology, and Clinical Care. J. Pharmacol. Exp. Ther. 313: 935-942 [Abstract] [Full Text]  
• Turner, L., Conway, A. J., Jimenez, M., Liu, P. Y., Forbes, E., McLachlan, R. I., Handelsman, D. J. (2003). Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men. J. Clin. Endocrinol. Metab. 88: 4659-4667 [Abstract] [Full Text]  
• Handelsman, D. J. (2003). Hormonal Male Contraception--Lessons from the East When the Western Market Fails. J. Clin. Endocrinol. Metab. 88: 559-561 [Full Text]  
• Greydanus, D. E., Patel, D. R., Rimsza, M. E. (2001). Contraception in the Adolescent: An Update. Pediatrics 107: 562-573 [Abstract] [Full Text]  
• Larimore, W. L., Stanford, J. B. (2000). Postfertilization Effects of Oral Contraceptives and Their Relationship to Informed Consent. Arch Fam Med 9: 126-133 [Abstract] [Full Text]  
• Eluf-Neto, J., Booth, M., Baird, D. T., Glasier, A. (1993). Hormonal Contraception. NEJM 329: 1501-1502 [Full Text]